Le Lézard
Classified in: Health
Subjects: CCA, FVT

Genomma Lab Internacional S.A.B. de C.V. Second Quarter 2024 Earnings Results Conference Call


MEXICO CITY, July 2, 2024 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company") today announced that it will report its Second Quarter 2024 Earnings Results on Wednesday, July 24, 2024, after the Mexican Stock Exchange (BMV) close. The company also announced that it will hold a conference call on Thursday, July 25, 2024, at 1 p.m. ET to discuss its quarterly financial results.

Presenters: Mr. Marco Sparvieri, Chief Executive Officer
Mr. Antonio Zamora, Chief Financial Officer
Christianne Ibanez, Investor Relations Officer

Date: Thursday, July 25, 2024

Time: 1:00 p.m. (ET) / 11:00 a.m. (Mexico City Time)

Webcast: To register please access via direct link
(You will receive an email confirmation with an invitation)

About Genomma Lab Internacional
Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker "LAB B" (Bloomberg: LABB:MM).

Note on Forward-Looking Statements
This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Genomma Lab Internacional, S.A.B. de C.V.


These press releases may also interest you

at 18:05
Teva Pharmaceutical Industries Ltd. announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live...

at 18:05
BetterLife Pharma Inc. ("BetterLife" or the "Company") , an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, announced that it has closed a non-brokered private placement,...

at 18:00
Global technology2use company CHG-MERIDIAN continues its strong growth path in Australia and New Zealand (ANZ) with the acquisition of Maia Financial Pty Limited's (Maia Financial) asset portfolio on June...

at 17:45
The global load monitoring systems market size is estimated to grow by USD 820.9 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 4.34% during the forecast period. Increasing use of load monitoring...

at 17:31
DelveInsight's PD-(L)1 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging PD-(L)1...

at 17:30
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that on July 1, 2024, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock...



News published on and distributed by: